GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

GSK GSK1.77%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...

GSK will use AI, dual sourcing to offset tariff hit Q1 results better-than-expected Shares up 3.8% Maintains 2025 turnover and profit forecasts April 30 (Reuters) - GSK (GSK.L), opens new tab on ...

GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...

Wave Life Sciences (NASDAQ:WVE) lost ~21% in the premarket on Wednesday after the company announced data from a Phase 1b/2a trial for its RNA-editing therapy WVE-006 developed with GSK (NYSE:GSK) for ...